Last reviewed · How we verify
SAP-001
At a glance
| Generic name | SAP-001 |
|---|---|
| Also known as | SAP-001 tablet, Xanthine Oxidase Inhibitor, Colchicine |
| Sponsor | Shanton Pharma Pte. Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function (PHASE1, PHASE2)
- Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001. (PHASE2)
- SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects (PHASE1)
- Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients (PHASE2)
- Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAP-001 CI brief — competitive landscape report
- SAP-001 updates RSS · CI watch RSS
- Shanton Pharma Pte. Ltd. portfolio CI